VC: FoldRX lands $43M in VC

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

FoldRx Pharmaceuticals
Cambridge, CA

$43M
Second

Texas Pacific Group Ventures and Alta Partners

The funding will support clinical trials for FoldRx's lead drug compound, Fx-1006A, which is finishing an early-stage trial to treat diseases of protein misfolding in the brain or heart.

Lux Biosciences
Jersey City

$36M
First

HBM Partners AG, Novo A/S, and SV Life Sciences

Isotechnika has grated Lux rights to develop and commercialize Isotechnika's Phase III product candidate ISA247 for the treatment and prophylaxis of all ophthalmic diseases.

U3 Pharma
Germany

$34M
Third

Life Sciences Partners

U3 has been developing antibody-based targeted cancer therapeutics. Its lead products are nearing the clinic.